论文部分内容阅读
目的:研究Angiostatin对黑色素瘤的治疗作用.方法:从人血浆组分Ⅲ中用亲和层析的方法分离Plasminogen和通过离子交换层析和分子筛技术得到弹性蛋白酶纯品.经此酶分离Plasminogen进行有限酶解,产物经亲和层析分离得到Angio-statin.结果:体外实验表明,Angiostatin能显著抑制牛主动脉弓内皮细胞的增殖.体内实验发现,以0.6 mg/kg·d的剂量腹腔注射14d后,B16黑色素瘤生长抑制率达77%(P<0.05);以小鼠尾静脉注射的方法建立黑色素瘤转移模型,采用同样的方法冶疗18d后,B16黑色素瘤的肺转移率降低了65%(P<0.05).结论:本研究为Angiostatin用于黑色素瘤的治疗提供了实验依据,说明Angiostin在肿瘤治疗方面有着广泛的应用前景.
Objective: To study the therapeutic effect of angiostatin on melanoma.Methods: Plasminogen was isolated from human plasma fraction Ⅲ by affinity chromatography and purified by ion-exchange chromatography and molecular sieve to obtain the pure elastase. Plasminogen was separated by this enzyme Angio-statin was isolated by affinity chromatography.Results: In vitro experiments showed that Angiostatin can significantly inhibit the proliferation of bovine aortic arch endothelial cells.In vivo experiments found that 0.6 mg / kg · d dose after intraperitoneal injection of 14d , B16 melanoma growth inhibition rate of 77% (P <0.05); mouse tail vein injection of melanoma metastasis model established by the same method of treatment 18d, B16 melanoma lung metastasis rate decreased by 65% (P <0.05) .Conclusion: This study provides an experimental basis for the treatment of melanoma with Angiostatin, which shows that Angiostin has a wide range of applications in the treatment of cancer.